Owlstone Medical has raised US$59m in a Series D financing round. The proceeds will be used to continue development of the company’s breath biopsy tests.
https://european-biotechnology.com/wp-content/uploads/2024/04/coronavirus-4952102_1920.jpg12801920Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2021-09-07 09:17:002021-09-07 09:17:00Owlstone: US$59m for breath biopsy development
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-09-06 15:22:122021-09-06 15:22:12Byondis with new Senior Director
The EU Commission and AstraZeneca have settled their ongoing legal dispute over the supply of COVID-19 vaccine doses. They agreed to a new delivery schedule.
Swiss rare disease specialist VectivBio Holding AG is taking over US biotech Comet Therapeutics Inc. for an undisclosed amount. Comet focusses on treatments for metabolic diseases.
With new backing from large pharma, rising investors interest, and new incubators on stage, the AMR community is now urging policy makers worldwide to bring pull incentives into reality.
https://european-biotechnology.com/wp-content/uploads/2024/04/2021_09_02_amrconf.jpg405720Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-08-30 05:46:002021-08-30 05:46:00Call for pull incentives to get started
https://european-biotechnology.com/wp-content/uploads/2024/04/Cardior_Pharma.jpg6671000Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-08-24 10:17:172021-08-24 10:17:17Cardior bags €64m in Series B Financing
https://european-biotechnology.com/wp-content/uploads/2024/04/merck-hq-outdoor.jpg10801920Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2021-08-24 10:00:002021-08-24 10:00:00Yet another blow to Merck’s cancer hopeful
UK-based start-up Beckley Psytech has completed an upsized Series B financing, raising €68m (US$80m). Proceeds will go towards the company’s pipeline of psychedelic compounds dedicated to addressing neurological and psychiatric disorders.
Owlstone: US$59m for breath biopsy development
Latest NewsOwlstone Medical has raised US$59m in a Series D financing round. The proceeds will be used to continue development of the company’s breath biopsy tests.
Byondis with new Senior Director
AppointmentsTimo van den Berg is the new senior director Immuno-Oncology Research and Development at Byondis B.V. He joined the company at beginning
EU ends litigation with AstraZeneca
Latest NewsThe EU Commission and AstraZeneca have settled their ongoing legal dispute over the supply of COVID-19 vaccine doses. They agreed to a new delivery schedule.
EuropaBio lobbies for better Orphan Drug rules
Latest NewsEuropaBio has responded to the European Commission’s public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.
VectivBio expands rare disease pipeline
Latest NewsSwiss rare disease specialist VectivBio Holding AG is taking over US biotech Comet Therapeutics Inc. for an undisclosed amount. Comet focusses on treatments for metabolic diseases.
Call for pull incentives to get started
Latest NewsWith new backing from large pharma, rising investors interest, and new incubators on stage, the AMR community is now urging policy makers worldwide to bring pull incentives into reality.
ADC Therapeutics: US$325m for ADC royalties
Latest NewsADC Therapeutics is set to receive up to US$325m for a royalty share in its antibody drug conjugates Zynlonta and Cami.
Cardior bags €64m in Series B Financing
Latest NewsCardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
Yet another blow to Merck’s cancer hopeful
Latest NewsGSK-partnered Merck is throwing in the towel for a Phase II trial of its immunotherapy contender bintrafusp alfa after disappointing results.
Beckley Psytech: €68m for psychedelic meds
Latest NewsUK-based start-up Beckley Psytech has completed an upsized Series B financing, raising €68m (US$80m). Proceeds will go towards the company’s pipeline of psychedelic compounds dedicated to addressing neurological and psychiatric disorders.